Jin Suk Han

Jin Suk Han

Auto-generated profile, based on publicly available information

Jin Suk Han

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
KJKwon Wook Joo
Kwon Wook Joo
Sejoong KimSejoong Kim
Sejoong Kim
SAShin Young Ahn
Shin Young Ahn
HCHo Jun Chin
Ho Jun Chin
DCDong-Wan Chae
Dong-Wan Chae
KNKi Young Na
Ki Young Na
Background: The inhibition of dipeptidyl peptidase (DPP) IV shows protective effects on tissue injury of the heart, lung, and kidney. Forkhead box O (FoxO) transcriptional factors regulate cellular differentiation, growth, survival, the cell cycle, metabolism, and oxidative stress. The aims of this study were to investigate whether the DPP IV inhibitor sitagliptin could attenuate kidney injury and to evaluate the status of FoxO3a signaling in the rat remnant kidney model. Methods: Rats were received two-step surgery of 5/6 renal mass reduction and fed on an oral dose of 200 mg/kg/day sitagliptin for 8 weeks. Before and after the administration of sitagliptin, physiologic parameters were measured. After 8 weeks of treatment, the kidneys were harvested. Results: The sitagliptin treatment attenuated renal dysfunction. A histological evaluation revealed that glomerulosclerosis and tubulointerstitial injury were significantly decreased by sitagliptin. Sitagliptin decreased DPP IV activity and increased the renal expression of glucagon-like peptide-1 receptor (GLP-1R). The subtotal nephrectomy led to the activation of phosphatidylinositol 3-kinase (PI3K)-Akt and FoxO3a phosphorylation, whereas sitagliptin treatment reversed these changes, resulting in PI3K-Akt pathway inactivation and FoxO3a dephosphorylation. The renal expression of catalase was increased and the phosphorylation of c-Jun N-terminal kinase (JNK) was decreased by sitagliptin. Sitagliptin treatment reduced apoptosis by decreasing cleaved caspase-3 and −9 and Bax levels and decreased macrophage infiltration. Conclusions: In rat remnant kidneys, DPP IV inhibitor attenuated renal dysfunction and structural damage. A reduction of apoptosis, inflammation and an increase of antioxidant could be suggested as a renoprotective mechanism together with the activation of FoxO3a signaling. Therefore, DPP IV inhibitors might provide a promising approach for treating CKD, but their application in clinical practice remains to be investigated.

1 November 2007 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
KJKwon Wook Joo
Kwon Wook Joo
JLJay Wook Lee
Jay Wook Lee
HJHye Ryoun Jang
Hye Ryoun Jang
NHNam Ju Heo
Nam Ju Heo
UJUn Sil Jeon
Un Sil Jeon
JHJin Suk Han
Jin Suk Han

1 August 2004 in Kidney International
Verified
Journal Article
Open access
PDF file
SKSejoong Kim
Sejoong Kim
JLJay Wook Lee
Jay Wook Lee
JPJunghwan Park
Junghwan Park
KNKi Young Na
Ki Young Na
KJKwon Wook Joo
Kwon Wook Joo
JHJin Suk Han
Jin Suk Han
The minimum urine pH induced by NH4Cl loading has traditionally been the main criterion for the diagnosis of distal renal tubular acidosis (dRTA)1 x 1. Wrong, O. Distal renal tubular acidosis: The value of urinary pH, PCO2 and NH4+ measurements. Pediatr Nephrol. 1991; 5: 249–255 Crossref | PubMed | Scopus (22) | Google Scholar See all References . However, urine pH during systemic acidosis may be a misleading index for the assessment of metabolic acidosis because of the discrepancy between urine pH and urinary NH4+2 x 2. Richardson, R.M.A. and Halperin, M.L. The urine pH: A potential misleading diagnostic test in patients with hyperchloremic metabolic acidosis. Am J Kidney Dis. 1987; 10: 140–143 Abstract | Full Text PDF | PubMed | Scopus (29) | Google Scholar See all References . In acute acidosis, the rate of H+ secretion exceeds that of ammonia. In chronic metabolic acidosis, on the other hand, the increase in ammonia caused by augmented ammoniagenesis is relatively larger than the increase in H+ secretion3 x 3. Carlisle, E.J. and Donnelly, S.M. Halperin ML: Renal tubular acidosis (RTA): Recognize the ammonium defect and pHorget the urine pH. Pediatr Nephrol. 1991; 5: 242–248 Crossref | PubMed | Scopus (41) | Google Scholar See all References . In this context, the urine anion gap was proposed to be useful in the diagnosis of hyperchloremic metabolic acidosis4 x 4. Batlle, D.C., Hizon, M., Cohen, E. et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988; 318: 594–599 Crossref | PubMed | Scopus (144) | Google Scholar See all References . In addition, the NH4Cl loading test has a difficulty in clinical practice; oral NH4Cl frequently causes gastric irritation, and liver disease is a contraindication to the administration of NH4Cl5 x 5. Lash, J.P. and Arruda, J.A.L. Laboratory evaluation of renal tubular acidosis. Clin Lab Med. 1993; 13: 117–129 PubMed | Google Scholar See all References .

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJae Wook Lee
Jae Wook Lee
JLJeong Hwan Lee
Jeong Hwan Lee
NHNam Ju Heo
Nam Ju Heo
HCHae Il Cheong
Hae Il Cheong
JHJin Suk Han
Jin Suk Han
Lee JW, et al. J Korean Med Sci. 2016 Jan;31(1):47-54. https://doi.org/10.3346/jkms.2016.31.1.47

25 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HLHajeong Lee
Hajeong Lee
JLJeong Hwan Lee
Jeong Hwan Lee
SHSeung-Sik Hwang
Seung-Sik Hwang
SKSejoong Kim
Sejoong Kim
HCHo Jun Chin
Ho Jun Chin
NHNam Ju Heo
Nam Ju Heo
Lower potassium intake is considered to be correlated with diabetes incidence. However, few studies have investigated the effect of potassium intake on metabolic syndrome (MetS). Data was taken from the Korean National Health and Nutritional Examination Survey (2008–2010) using weighted adjustment. MetS was defined as per the revised National Cholesterol Education Program criteria. Homeostasis model assessment indices were calculated to diagnosis insulin resistance (IR). A total of 16,637 participants (44±0.25 years) were included. Women ingested lower amounts of potassium (2.71±0.02 g/day) than men (3.45±0.03 g/day). A curvilinear association between potassium intake and MetS prevalence was found among women. Women with less than the Adequate Intake (4.7 g/day) of potassium had an 11% risk reduction for MetS (adjusted odds ratio [OR], 0.89; 95% confidence interval [CI], 0.82–0.96; P = 0.004) and a 10% risk reduction for IR (OR, 0.90; 95% CI, 0.82–0.99; P = 0.026) for every 1 g/day potassium increase. Compared with the reference group (3.5–4.5 g/day), potassium intake was inversely associated with an increased risk of MetS (1.5–2.5 g/day; OR, 1.29; 95% CI, 1.02–1.63; P = 0.035; <1.5 g/day; OR, 1.40; 95% CI, 1.06–1.85; P = 0.017) and IR (<1.5 g/day; OR, 1.36; 95% CI, 1.05–1.76; P = 0.021). This relationship was more prominent in postmenopausal women, but not observed among men. Higher potassium intake is significantly associated with a lower MetS prevalence in women, and IR is believed to be connected.

27 July 2004 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
KJKwon Wook Joo
Kwon Wook Joo
UJUn Sil Jeon
Un Sil Jeon
Gheun-Ho KimGheun-Ho Kim
Gheun-Ho Kim
JPJungwhan Park
Jungwhan Park
YOYoon Kyu Oh
Yoon Kyu Oh
JHJin Suk Han
Jin Suk Han
Background. The antidiuretic effect of oxytocin in humans is controversial. Urinary excretion of aquaporin-2 (AQP2) can be used as an index of the action of vasopressin on the kidney. We investigated whether exogenous oxytocin affects urinary concentration and urinary AQP2 excretion in human beings. Methods. Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI). On the next day, 2 µg of 1-desamino-8-d-arginine vasopressin (dDAVP) was injected subcutaneously. Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis. Results. Urine volume and free water clearance were decreased, and urine osmolality was increased by the administration of oxytocin or dDAVP in the normal volunteers and CDI patients. Urinary AQP2 excretion was increased by oxytocin infusion in the normal volunteers (from 34±12 to 326±120 densitometry unit (DU)/2 h) and in the CDI group (from 8±2 to 227±92 DU/2 h) (P<0.05), but not in the NDI group. dDAVP also had a similar but more potent effect on the urinary excretion of AQP2 in the normal and CDI groups. Conclusions. Oxytocin has an antidiuretic effect and increases the urinary excretion of AQP2 in humans whose urinary concentration mechanism is preserved. These results suggest that AQP2 might have a regulatory role in the antidiuretic action of oxytocin in humans.